Novo Nordisk Files Additional Suits Against Illinois Med Spas and Weight Loss Clinics
Novo Nordisk has continued to target medical weight loss clinics and small businesses providing weight loss medications, filing lawsuits throughout 2024. Many providers, weight loss clinics, and med spas were caught off guard by claims of false advertising, trademark infringement, and unlawful sales of compounded versions of Ozempic and Wegovy. The lawsuits allege that some defendants falsely represent compounded medications as Novo Nordisk’s branded drugs.
I Don’t Want to be Sued; What Should I Do?
The FDA allows the use of compounded semaglutide as long as Ozempic and Wegovy remain on its drug shortages list. Providers and weight loss clinics must follow the FDA advisory to avoid legal risks.
- Obtain semaglutide only from compounding pharmacies while the branded drugs are on the shortage list.
- Ensure the pharmacy uses the base form of semaglutide, not salt forms.
- Be honest with patients about the shortage and explain that you use compounded semaglutide with the base form.
- Avoid false advertising. Do not use branded drug names if you are not providing those specific products.
If you have any questions or concerns about your medical weight loss practice’s marketing or prescribing of semaglutide, tirzepetide, or similar drugs, contact 1818 today. Call us at (312) 779-1818 or fill out our online contact form for further assistance and expert advice from our experienced attorneys can help you effectively navigate the weight loss clinic/ med spa process, protect your rights, and advocate for your best interests.
